News Agency
The Times

DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026

  • Written by PR Newswire

PARIS, May 20, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, today announced robust 3-month clinical data from its HERO-HTN-FIH study during a featured presentation at EuroPCR 2026. The interim results demonstrate that the HyperQure™ extravascular renal denervation (RDN) system provides a powerful and safe...

Read more: DeepQure Announces Robust 3-Month Results from HERO-HTN Clinical Study at EuroPCR 2026

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion